Scholarlink

Aim <p>We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.</p> Methods <p>An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023—June 2025.</p> Results <p>In total there were 27 responses. Methotrexate was selected most commonly for all scenarios &gt; 5&#xa0;years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).</p> Conclusion <p>In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis

  • 期刊论文

  • 发表日期：

    2025年10月1日

查看全文
  • Stephanie Bowe,
  • Michelle Murphy,
  • John Bourke,
  • Caitriona Ryan

摘要

Aim

We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.

Methods

An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023—June 2025.

Results

In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).

Conclusion

In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.